Irinotecan vs non‐irinotecan‐containing regimens: Tumour response
Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Irinotecan vs non‐irinotecan‐containing regimens Tumour response · people with advanced gastric cancer Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty). Chemotherapy for advanced gastric cancer (2017) · Cochrane Headline outcomes only | OR 1.72 [1.24, 2.4] | 10 studies · 1266 participants | Low |
Irinotecan vs non‐irinotecan‐containing regimens Tumour response ‐ Substitutive comparisons · people with advanced gastric cancer Irinotecan showed no clear difference in tumour response ‐ Substitutive comparisons compared with non‐irinotecan‐containing regimens (low certainty). Chemotherapy for advanced gastric cancer (2017) · Cochrane Headline outcomes only | OR 1.53 [0.93, 2.5] | 6 studies · 756 participants | Low |
Irinotecan vs non‐irinotecan‐containing regimens Tumour response ‐ Additive comparisons · people with advanced gastric cancer Irinotecan may leads to higher tumour response ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty). Chemotherapy for advanced gastric cancer (2017) · Cochrane Headline outcomes only | OR 2.18 [1.25, 3.8] | 3 studies · 345 participants | Low |
Irinotecan vs non‐irinotecan‐containing regimens Tumour response ‐ Other comparisons · people with advanced gastric cancer It is very uncertain whether irinotecan changes tumour response ‐ Other comparisons compared with non‐irinotecan‐containing regimens (very low certainty). Chemotherapy for advanced gastric cancer (2017) · Cochrane Headline outcomes only | OR 1.87 [0.89, 3.91] | 2 studies · 165 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.